Edition:
United States

People: Neogenomics Inc (NEO.OQ)

NEO.OQ on NASDAQ Stock Exchange Capital Market

14.14USD
1:55pm EDT
Change (% chg)

$0.33 (+2.39%)
Prev Close
$13.81
Open
$13.82
Day's High
$14.34
Day's Low
$13.82
Volume
47,648
Avg. Vol
117,490
52-wk High
$14.61
52-wk Low
$7.08

Brodie, Steven 

Dr. Steven G. Brodie, Ph.D., is Vice President - Operations of NeoGenomics, Inc. Dr. Brodie currently serves as our Vice President of Operations. He has previously served as the President of our Pharma Services Division, Laboratory Director for our Fort Myers, FL lab facility, Chief Scientific Officer and Director of Molecular Genetics and Cytogenetics. Prior to joining the Company, Dr. Brodie served as a Senior Director of Cytogenetics, Assistant Director of Molecular Genetics, and Scientific Director of Maternal Serum Screening at Quest Diagnostics (Specialty Laboratories) in Valencia California. In addition to his clinical responsibilities, he trained Pathology residents in genetic testing for Loma Linda University Medical Center as the Affiliate Rotation Director and the University of Southern California, Keck SOM as a Clinical Assistant Professor of Pathology. Prior to joining Quest Diagnostics, he held a variety of research and clinical positions at the National Institutes of Health, University of New Mexico School of Medicine, and the University of California Los Angeles David Geffen School of Medicine. Dr. Brodie was trained in Genetics at the University of California Los Angeles/Cedar-Sinai Medical Center medical genetics training program. He received a Ph.D. in Biomedical Sciences from the University of New Mexico School of Medicine and Clinical Molecular Genetics and Cytogenetics training at the University of California Los Angeles. Dr. Brodie is Board Certified by the American Board of Medical Genetics and Genomics and holds Directors Licenses in California, Florida, Tennessee, and New York.

Basic Compensation

Total Annual Compensation, USD 335,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 170,667
Fiscal Year Total, USD 505,667

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --